Appetite Suppressants and Valvular Heart Disease

@article{Weissman2001AppetiteSA,
  title={Appetite Suppressants and Valvular Heart Disease},
  author={N. Weissman},
  journal={The American Journal of the Medical Sciences},
  year={2001},
  volume={321},
  pages={285-291}
}
  • N. Weissman
  • Published 2001
  • Medicine
  • The American Journal of the Medical Sciences
The association between valvular heart disease and diet pills was discovered several years ago in a small cohort of patients. Subsequent uncontrolled surveys and reports suggested a prevalence of cardiac abnormalities as high as 30%. These results led to widespread concern by millions of appetite suppressant users and the withdrawal of both fenfluramine and dexfenfluramine from the market. Through this review of the literature, it becomes apparent that we have better defined the association… Expand
Drug-induced fibrotic valvular heart disease
TLDR
Results from clinical trials show that drug dose and treatment duration affect both the risk of developing the disease and its severity, and continued vigilance is necessary because several commonly prescribed treatments interact with serotonergic pathways. Expand
Pulmonary Hypertension Associated with Use of Phentermine
TLDR
Phentermine has been considered a relatively safe drug to treat obesity, and further investigation is needed to decide the safety and dosage of phentermine. Expand
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals
TLDR
Regurgitant valvulopathy was common in individuals exposed to fenfluramines, more frequent in females, and associated with duration of use in all valves assessed and the incidence of surgery appeared to be substantially increased compared with limited general population data. Expand
Drug-induced heart failure.
TLDR
A literature search was conducted to identify reports of new-onset HF and exacerbations of HF associated with medication use published from 1960 to January 2011, finding a variety of agents associated with drug-induced HF. Expand
Pharmacotherapy of obesity.
  • N. Finer
  • Medicine
  • Best practice & research. Clinical endocrinology & metabolism
  • 2002
TLDR
Advances in understanding of the mechanism of weight control, together with improved ways of evaluating anti-obesity drugs, has resulted in two effective compounds, sibutramine and orlistat, becoming available for clinical use. Expand
Weight management and current options in pharmacotherapy: orlistat and sibutramine.
TLDR
Current evidence supports their use as adjuncts to lifestyle modifications in the treatment of obesity, and sibutramine demonstrated a favorable efficacy and safety profile in randomized controlled trials. Expand
Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity
TLDR
The safety and efficacy of currently approved drug therapies have not been evaluated in children and elderly patient populations and there is limited information in adolescents, whilst the long-term safety of current and potential new drug therapies in adults will require several years of postmarketing surveillance to fully elucidate their adverse effect profiles. Expand
Cardiac Valvulopathy Associated with Pergolide Use
TLDR
Pergolide therapy is associated with an increased risk of developing cardiac valvulopathy but the true incidence and importance of this remains unknown and further prospective studies are needed with standardized assessments of echocardiograms. Expand
New Perspectives and Pharmacotherapies
There is a widespread epidemic of obesity in the United States, which has been associated with an increased risk of diabetes mellitus, cancer, and cardiovascular diseases. Although lifestyleExpand
Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study
TLDR
The cardiovascular safety profile of low‐dose fenfluramine when used in a pediatric population to reduce seizure frequency in patients with Dravet syndrome is characterized. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
TLDR
The use of fenfluramine or dexfen fluramine, particularly for four months or longer, is associated with an increased risk of newly diagnosed cardiac-valve disorders, particularly aortic regurgitation. Expand
Natural History of Valvular Regurgitation 1 Year after Discontinuation of Dexfenfluramine Therapy
TLDR
Assessing change in valvular regurgitation by using a side-by-side reading method 1 year after dexfenfluramine therapy was discontinued found no statistical difference among the groups, according to U.S. Food and Drug Administration criteria. Expand
Risk for Valvular Heart Disease among Users of Fenfluramine and Dexfenfluramine Who Underwent Echocardiography before Use of Medication
TLDR
To estimate the risk for medication-associated valvular heart disease, users of fenFLuramine or dexfenfluramine who underwent echocardiography before beginning therapy with these medications were identified and compared these eChocardiograms to those obtained after therapy was discontinued. Expand
Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.
TLDR
The findings suggest that valvular abnormalities in patients who took fenfluramine-phentermine primarily involve those who had taken these medications for >6 months and predominantly results in mild aortic regurgitation. Expand
Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months.
TLDR
Phen-fen therapy is associated with a low prevalence of significant valvular regurgitation, comparable to the normal offspring in the Framingham Heart Study, who are similar in age, gender, and geographical location. Expand
The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
TLDR
Obese patients who took fen fluramine and phentermine, dexfenfluramine alone, or dexfanfluramines and phen termine for various periods had a significantly higher prevalence of cardiac valvular insufficiency than a matched group of control subjects. Expand
Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota.
TLDR
The hypotheses that valvular heart disease among fenfluramine users may be less common than previously estimated, that serotonin excess may play a role in valve pathology, and that a patient's response to anorexigens and other medications may serve as a marker for increased risk are raised. Expand
Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.
TLDR
The data used by FDA in its decision to request voluntary withdrawal of these drugs from the market is summarized, and interim public health recommendations for persons exposed to these drugs are presented. Expand
Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
TLDR
Evaluating cardiovascular status and the prevalence of valvular abnormalities, as assessed by clinical cardiovascular parameters and echocardiography, in patients treated for obesity with dexfenfluramine or phentermine/fen Fluramine indicates that use of dexfinfluramines and phentermin/fen fluramine is associated with an increase in the prevalenceof AR, but was not associated with a increase inThe prevalence of MR using FDA criteria or with serious cardiac events. Expand
Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine.
BACKGROUND Valve regurgitation has been associated with dexfenfluramine, but its prevalence and severity are uncertain. Additional factors that may contribute to valve regurgitation in patientsExpand
...
1
2
3
...